In this context, inhibitors targeting different RNA modifications, such as FTO or PUS7 inhibitors, have demonstrated promising results in independently suppressing glioblastoma and reducing self-renewal (Cui et al., 2017, 2021). This evidence concerns the gene PUS7 and glioblastoma.